Psychopharmacology View Homepage


Ontology type: schema:Periodical     


Journal Info

START YEAR

1933

PUBLISHER

Springer Berlin Heidelberg

LANGUAGE

en

HOMEPAGE

https://link.springer.com/journal/213

Recent publications latest 20 shown

  • 2022-11-18 Systematic review of studies using platelet serotonin content to assess bioeffect of serotonin reuptake inhibitors at the serotonin transporter
  • 2022-11-17 Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction
  • 2022-11-04 Elucidating the reinforcing effects of nicotine: a tribute to Nadia Chaudhri
  • 2022-11-02 Medial orbitofrontal cortical regulation of different aspects of Pavlovian and instrumental reward seeking
  • 2022-10-20 Learning processes in relapse to alcohol use: lessons from animal models
  • 2022-10-15 A double-blind, randomized, placebo-controlled test of the effects of cannabidiol on fear elicited by a 10% carbon dioxide-enriched air breathing challenge
  • 2022-10-14 Repeated dosing with cocaine produces strain-dependent effects on responding for conditioned reinforcement in Collaborative Cross mice
  • 2022-10-13 Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis
  • 2022-10-13 Reinstatement of Pavlovian responses to alcohol cues by stress
  • 2022-10-12 Rose Bengal inhibits β-amyloid oligomers-induced tau hyperphosphorylation via acting on Akt and CDK5 kinases
  • 2022-10-11 Food for thought: diet-induced impairments to decision-making and amelioration by N-acetylcysteine in male rats
  • 2022-10-05 Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis
  • 2022-10-04 Duration- and sex-dependent neural circuit control of voluntary physical activity
  • 2022-10-03 Sexually dimorphic role of circadian clock genes in alcohol drinking behavior
  • 2022-10-03 The nucleus accumbens dopamine increase, typically triggered by sexual stimuli in male rats, is no longer produced when animals are sexually inhibited due to sexual satiety
  • 2022-10-03 The relationship between executive functioning and addictive behavior: new insights from a longitudinal community study
  • 2022-10-03 Reinforcing effects of phenethylamine analogs found in dietary supplements
  • 2022-10-01 Differences in attentional bias to smoking-related, affective, and sensation-seeking cues between smokers and non-smokers: an eye-tracking study
  • 2022-09-30 A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders
  • 2022-09-30 Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson’s disease
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "contentRating": [
          {
            "author": "snip", 
            "ratingValue": "1.1200000047683716", 
            "type": "Rating"
          }, 
          {
            "author": "sjr", 
            "ratingValue": "1.100000023841858", 
            "type": "Rating"
          }
        ], 
        "description": "

    Official Journal of\u00a0the European Behavioural Pharmacology Society\u00a0(EBPS)

    Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:

    Human\u00a0Psychopharmacology: Experimental

    This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans.\u00a0 The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics.\u00a0 Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.

    Human\u00a0Psychopharmacology: Clinical and Translational

    This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.

    Preclinical psychopharmacology: Behavioral and Neural

    This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.

    Preclinical Psychopharmacology: Translational

    This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.

    Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic

    This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.\u00a0

    The journal welcomes submissions in all of these fields.

    Details Concerning the Submission and Publication Procedures:
    - No Page Charges
    -\u00a0No Fees for Online Color Images
    -\u00a0Optional Color Images in Print \u2013 EUR 950/USD 1150. VAT or local taxes will be added where applicable.
    - Optional Open Access Publication Fee (APC) - EUR 2990/USD 3760/GBP 2490. VAT or local taxes will be added where applicable.

    ", "editor": [ { "familyName": "Pizzagalli", "givenName": "Diego", "type": "Person" } ], "id": "sg:journal.1085440", "inLanguage": [ "en" ], "isAccessibleForFree": false, "issn": [ "0033-3158", "1432-2072" ], "license": "Hybrid", "name": "Psychopharmacology", "productId": [ { "name": "dimensions_id", "type": "PropertyValue", "value": [ "85440" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "7608025" ] }, { "name": "nsd_ids_id", "type": "PropertyValue", "value": [ "343115" ] }, { "name": "era_ids_id", "type": "PropertyValue", "value": [ "14856" ] } ], "publisher": { "name": "Springer Berlin Heidelberg", "type": "Organization" }, "publisherImprint": "Springer", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1085440" ], "sdDataset": "journals", "sdDatePublished": "2022-11-24T21:22", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/journal/journal_0.jsonl", "startYear": "1933", "type": "Periodical", "url": "https://link.springer.com/journal/213" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1085440'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1085440'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1085440'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1085440'


     

    This table displays all metadata directly associated to this object as RDF triples.

    56 TRIPLES      20 PREDICATES      26 URIs      22 LITERALS      9 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1085440 schema:contentRating Nbfb98ebf96fe4b07b421b346543278f5
    2 Nf089171672a149fcbc8a76d0e0fa3165
    3 schema:description <p>Official Journal of the European Behavioural Pharmacology Society (EBPS)</p><p><i>Psychopharmacology</i> is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:</p><p><b>Human Psychopharmacology: Experimental</b></p><p>This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans.  The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics.  Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.</p><p><b>Human Psychopharmacology: Clinical and Translational</b></p><p>This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.</p><p><b>Preclinical psychopharmacology: Behavioral and Neural</b></p><p>This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels. </p><p><b>Preclinical Psychopharmacology: Translational</b></p><p>This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.</p><p><b>Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic</b></p><p>This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome. </p><p>The journal welcomes submissions in all of these fields.</p><p>Details Concerning the Submission and Publication Procedures:<br/>- No Page Charges<br/>- No Fees for Online Color Images<br/>- <b>Optional</b> Color Images in Print – EUR 950/USD 1150. VAT or local taxes will be added where applicable.<br/>- <b>Optional</b> Open Access Publication Fee (APC) - EUR 2990/USD 3760/GBP 2490. VAT or local taxes will be added where applicable.</p>
    4 schema:editor N5d8a47ec5a8c415aad7fa2d51eaff9ef
    5 schema:inLanguage en
    6 schema:isAccessibleForFree false
    7 schema:issn 0033-3158
    8 1432-2072
    9 schema:license Hybrid
    10 schema:name Psychopharmacology
    11 schema:productId N24f1eb56d0a946d8a50ce69102abe014
    12 N5b1027cb6a0048b386d26bd251fa9fcc
    13 N8117182162e042a9b8708cc0c7201e27
    14 Nd60149e0e8ac4dd6976b5112938582c6
    15 schema:publisher Nda5a245928264b9a8cac5c3c609ea0bf
    16 schema:publisherImprint Springer
    17 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1085440
    18 schema:sdDatePublished 2022-11-24T21:22
    19 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    20 schema:sdPublisher Nb29a8edec2d84391819cdb9aa311548c
    21 schema:startYear 1933
    22 schema:url https://link.springer.com/journal/213
    23 sgo:license sg:explorer/license/
    24 sgo:sdDataset journals
    25 rdf:type schema:Periodical
    26 N24f1eb56d0a946d8a50ce69102abe014 schema:name nsd_ids_id
    27 schema:value 343115
    28 rdf:type schema:PropertyValue
    29 N5b1027cb6a0048b386d26bd251fa9fcc schema:name era_ids_id
    30 schema:value 14856
    31 rdf:type schema:PropertyValue
    32 N5d8a47ec5a8c415aad7fa2d51eaff9ef rdf:first N8267c7324ccf42cf9b050c529af3ad19
    33 rdf:rest rdf:nil
    34 N6e8c2bb6cf4d4e1683fa368fffc9f28c rdf:first snip
    35 rdf:rest rdf:nil
    36 N768790fbfd83433bace652bf4c59cffd rdf:first sjr
    37 rdf:rest rdf:nil
    38 N8117182162e042a9b8708cc0c7201e27 schema:name dimensions_id
    39 schema:value 85440
    40 rdf:type schema:PropertyValue
    41 N8267c7324ccf42cf9b050c529af3ad19 schema:familyName Pizzagalli
    42 schema:givenName Diego
    43 rdf:type schema:Person
    44 Nb29a8edec2d84391819cdb9aa311548c schema:name Springer Nature - SN SciGraph project
    45 rdf:type schema:Organization
    46 Nbfb98ebf96fe4b07b421b346543278f5 schema:author N6e8c2bb6cf4d4e1683fa368fffc9f28c
    47 schema:ratingValue 1.1200000047683716
    48 rdf:type schema:Rating
    49 Nd60149e0e8ac4dd6976b5112938582c6 schema:name nlm_unique_id
    50 schema:value 7608025
    51 rdf:type schema:PropertyValue
    52 Nda5a245928264b9a8cac5c3c609ea0bf schema:name Springer Berlin Heidelberg
    53 rdf:type schema:Organization
    54 Nf089171672a149fcbc8a76d0e0fa3165 schema:author N768790fbfd83433bace652bf4c59cffd
    55 schema:ratingValue 1.100000023841858
    56 rdf:type schema:Rating
     




    Preview window. Press ESC to close (or click here)


    ...